EGFR and neoplasm: To investigate the clinical association of LAPTM4B and ATP1A1 with acquired EGFR-TKI resistance, we further analyzed paired tumor biopsies from six patients with EGFR-mutant NSCLC collected before treatment and after acquisition of EGFR-TKI resistance.